JQ1 decreases leukemic burden and improves survival in B-ALL primary human xenografts. (A) Immunohistochemistry for c-Myc30 and phospho-STAT5 (pSTAT5) in spleen samples obtained after 5-day treatment or at the moribund state. (B) Quantitative PCR of MYC and IL7R expression in leukemia cells harvested from spleens of mice treated for 5 days with JQ1 or vehicle (Veh). Error bars represent ± SEM; n = 3 PCR samples normalized to vehicle-treated sample. (C) Flow cytometry of splenic cells obtained after 5-day treatment with JQ1 or vehicle. Scatter plots on the left show overall IL7R expression versus hCD45. The histogram on the right is a quantification of total IL7R expression. (D) Peripheral blood cell counts after 5 days of treatment (n = 6 in each arm, mean levels for each sample marked). WBC indicates white blood cells. (E) Survival of engrafted mice treated with JQ1 (n = 9) or vehicle (n = 9).
